Deviating HER2 status between primary breast carcinomas and their liver metastases
HER2 heterogeneity is present in both primary breast cancer and liver metastases. Ongoing monitoring of molecular markers, particularly HER2 expression, remains essential for breast cancer patients, as it may provide opportunities for therapeutic intervention.
Authors
- Xingmei Guo (ORCID: https://orcid.org/0000-0003-4517-9676)
- Jianhong Tu
- Wei Qu
- Yuexia Chen
- Suqing Cheng
- Yang Liu (ORCID: https://orcid.org/0000-0001-9167-514X)
Institutions
- Third Hospital of Nanchang (CN)
- Wuxi No.2 People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-11-21
- DOI
- https://doi.org/10.3389/fonc.2025.1723716
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05